B
진양제약
007370KOSDAQ의약품 제조업61.0 / 100
Reference Date: 2026-06-10
Financial Score32.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Plunged 18.0% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Jinyang Pharmaceutical primarily engages in the manufacturing and sales of pharmaceutical products, operating in a high-value, R&D-driven industry. However, growth is constrained by government price controls and intensified competition, with new drug development and international market expansion seen as key future growth drivers.
Number of Employees
219people
Average Salary
58.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
2.18Industry Average 11.938.0Point
Half of industry avg (excellent)
PBR
0.35Industry Average 0.897.0Point
Half of industry avg (excellent)
ROE
15.93Industry Average 4.017.0Point
4.0x industry avg (excellent)
Debt Ratio
12.43Industry Average 12.434.0Point
In line with industry avg
Trend 2023~20256.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲13.5% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼24.8% (2-year basis)
ROE Trend
4.0 / 4
Avg ROE 19.8% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 3,985Won52-week high 6,74052-week low 3,985
1-month return0.0Point
1m -18.00% (strong drop)
Volume trend5.0Point
Volume flat
Detailed Disclosure
6 totalPositive 0Neutral 6Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-06-05
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
- Neutral전환가액의조정2026-05-26
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-18
- Neutral주식등의대량보유상황보고서(일반)2026-05-18